Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Organisation › Details

Actelion Ltd. (SIX: ATLN)

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). *

 

Period Start 1997-12-17 established
  Group Johnson & Johnson (JnJ) (Group)
Products Industry pharmaceutical
  Industry 2 Tracleer®
Persons Person Clozel, Jean-Paul (Actelion 200607 CEO)
  Person 2 Muller, André C. (Idorsia 201706– CFO before Actelion 201309– CFO before Pierre Fabre CFO)
     
Region Region Allschwil BL
  Country Switzerland
  Street 16 Gewerbestr.
  City 4123 Allschwil BL
  Tel +41-61-565-6262
    Address record changed: 2018-07-24
     
Basic data Employees F: 1,001 to 5,000 (2014-12-31)
  Currency CHF
  Annual sales 2,412,198,000 (revenue, net, total, consolidated (2016) 2016-12-31)
  Profit 694,835,000 (2016-12-31)
  Cash 495,380,000 (2016-12-31)
     
    * Document for �About Section�: Actelion Ltd.. (10/24/11). "Press Release: Actelion Provides Update on Judgment in Asahi Kasei Litigation". Allschwil.
     
   
Record changed: 2018-10-31

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Johnson & Johnson (JnJ) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px




» top